{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:03:03Z","timestamp":1788814983967,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["21153MFDS607"],"award-info":[{"award-number":["21153MFDS607"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["2021-2025"],"award-info":[{"award-number":["2021-2025"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00405650"],"award-info":[{"award-number":["RS-2024-00405650"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jaip.2025.05.060","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:30:52Z","timestamp":1749321052000},"page":"2025-2032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk for Angioedema With the Use of Dipeptidyl Peptidase 4 Inhibitors: A Population-Based Cohort Study"],"prefix":"10.1016","volume":"13","author":[{"given":"Bin","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyesung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Min","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-7525","authenticated-orcid":false,"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.05.060_bib1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"Deacon","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jaip.2025.05.060_bib2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13098-024-01412-x","article-title":"The multiple actions of dipeptidyl peptidase 4 (DPP-4) and its pharmacological inhibition on bone metabolism: a review","volume":"16","author":"Pechmann","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jaip.2025.05.060_bib3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.anai.2011.02.012","article-title":"DPP-4 inhibitors and angioedema: a cause for concern?","volume":"106","author":"Byrd","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.05.060_bib4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.7326\/L16-0649","article-title":"Sitagliptin and angioedema","volume":"167","author":"Arcani","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaip.2025.05.060_bib5","series-title":"Januvia (sitagliptin) [prescribing information]","year":"2024"},{"key":"10.1016\/j.jaip.2025.05.060_bib6","series-title":"Galvus (vildagliptin) [prescribing information]","year":"2013"},{"key":"10.1016\/j.jaip.2025.05.060_bib7","series-title":"Onglyza (saxagliptin) [prescribing information]","year":"2009"},{"key":"10.1016\/j.jaip.2025.05.060_bib8","series-title":"Nesina (alogliptin) [prescribing information]","year":"2013"},{"key":"10.1016\/j.jaip.2025.05.060_bib9","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.05.060_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12948-021-00164-7","article-title":"Angioedema associated with dipeptidyl peptidase-IV inhibitors","volume":"19","author":"Cassano","year":"2021","journal-title":"Clin Mol Allergy"},{"key":"10.1016\/j.jaip.2025.05.060_bib11","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjp.0707641","article-title":"Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema","volume":"153","author":"Fryer","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaip.2025.05.060_bib12","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaci.2023.11.921","article-title":"Meta-analysis of ACE inhibitor-induced angioedema identifies novel risk locus","volume":"153","author":"Mathey","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.060_bib13","article-title":"Association between vildagliptin and risk of angioedema, foot ulcers, skin lesions, hepatic toxicity, and serious infections in patients with type 2 diabetes mellitus: a European multidatabase, noninterventional, postauthorization safety study","volume":"2","author":"Williams","year":"2019","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.jaip.2025.05.060_bib14","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/HYPERTENSIONAHA.109.134197","article-title":"Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema","volume":"54","author":"Brown","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.jaip.2025.05.060_bib15","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.jaip.2020.03.046","article-title":"Angioedema-related emergency department visits in the United States: epidemiology and time trends, 2006-2015","volume":"8","author":"Carrillo-Martin","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.060_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.060_bib17","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1111\/dom.15196","article-title":"Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom","volume":"25","author":"Abrahami","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jaip.2025.05.060_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12016-025-09027-4","article-title":"Hereditary angioedema with normal C1 inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and Treatment","volume":"68","author":"Zuraw","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2025.05.060_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1130625","article-title":"DPP-4 inhibitors for treating T2DM\u2014hype or hope? An analysis based on the current literature","volume":"10","author":"Saini","year":"2023","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jaip.2025.05.060_bib21","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/HYPERTENSIONAHA.108.110270","article-title":"Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors","volume":"51","author":"Miller","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.jaip.2025.05.060_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2022.10.033","article-title":"Comparative risk of angioedema with sacubitril-valsartan vs renin-angiotensin-aldosterone inhibitors","volume":"81","author":"Eworuke","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaip.2025.05.060_bib23","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/2013.jamainternmed.34","article-title":"Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system","volume":"172","author":"Toh","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaip.2025.05.060_bib24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.jaip.2025.05.060_bib25","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.jaip.2025.05.060_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4093\/dmj.2022.0106","article-title":"Diabetes Fact Sheet in Korea 2021","volume":"46","author":"Bae","year":"2022","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jaip.2025.05.060_bib27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc17-1414","article-title":"Long-term trends in antidiabetes drug usage in the U.S.: real-world evidence in patients newly diagnosed with type 2 diabetes","volume":"41","author":"Montvida","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaip.2025.05.060_bib28","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/dmrr.2502","article-title":"Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus","volume":"30","author":"Hirshberg","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.jaip.2025.05.060_bib29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/1573399813666170214113856","article-title":"Dipeptidyl peptidase-4 inhibitor induced angioedema\u2014an overlooked adverse drug reaction?","volume":"14","author":"Scott","year":"2018","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.jaip.2025.05.060_bib30","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaip.2018.04.022","article-title":"Angioedema due to bradykinin dysregulation","volume":"6","author":"Cicardi","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.060_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11906-018-0859-x","article-title":"ACE inhibitor-induced angioedema: a review","volume":"20","author":"Kostis","year":"2018","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.jaip.2025.05.060_bib32","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.3390\/ijerph20032607","article-title":"Antidiabetic drug prescription pattern in hospitalized older patients with diabetes","volume":"20","author":"Ardoino","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jaip.2025.05.060_bib33","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4735876","article-title":"Prescribing patterns of antihypertensives for treatment-na\u00efve patients in South Korea: from Korean NHISS claim data","volume":"2019","author":"Kim","year":"2019","journal-title":"Int J Hypertens"},{"key":"10.1016\/j.jaip.2025.05.060_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13098-024-01570-y","article-title":"Interaction between dipeptidyl-peptidase-4 inhibitors and drugs acting on renin angiotensin aldosterone system for the risk of angioedema: a pharmacovigilance assessment using disproportionality and interaction analyses","volume":"17","author":"Sridharan","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jaip.2025.05.060_bib35","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1016\/j.jaip.2020.03.015","article-title":"Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibitor\u2013induced angioedema: a disproportionality analysis of the WHO pharmacovigilance database","volume":"8","author":"Lepelley","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.060_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-17366-x","article-title":"Pharmacovigilance study of the association between dipeptidyl peptidase\u20134 inhibitors and angioedema using the FDA Adverse Event Reporting System (FAERS)","volume":"12","author":"Ohyama","year":"2022","journal-title":"Sci Rep"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825005379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825005379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:57:00Z","timestamp":1778853420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825005379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2213219825005379"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.05.060","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk for Angioedema With the Use of Dipeptidyl Peptidase 4 Inhibitors: A Population-Based Cohort Study","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.05.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}